Alm. Brand A/S
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S share buy-back program
Transactions during 28 April 2025 – 02 May 2025
On 5 March 2025, Alm. Brand A/S announced a share buy-back program of up to DKK 835.2 million, as described in company announcement no. 21/2025.
The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.
The following transactions were made under the share buy-back program during week number 18:
| Number of shares bought | Average purchase price | Amount (DKK) | |
| Accumulated, last announcement | 8,870,000 | 15.81 | 138,478,500 |
| 28 April 2025 | 250,000 | 15.38 | 3,845,000 |
| 29 April 2025 | 250,000 | 15.40 | 3,850,000 |
| 30 April 2025 | 260,000 | 15.59 | 4,053,400 |
| 01 May 2025 | 260,000 | 15.38 | 3,998,800 |
| 02 May 2025 | 280,000 | 15.37 | 4,303,600 |
| Total, week number 18 | 1,300,000 | 15.42 | 20,050,800 |
| Accumulated under the program | 10,170,000 | 15.76 | 158,529,300 |
With the transactions stated above Alm. Brand A/S holds a total of 103,589,230 own shares corresponding to 6.72 % of the total number of outstanding shares.
Contact
Please direct any questions regarding this announcement to:
Investors and equity analysts:
Head of Investor Relations & ESG
Mads Thinggaard
Mobile no. +45 2025 5469
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Resonance Consultancy7.5.2025 06:30:00 CEST | Press release
Resonance Consultancy Reveals Europe’s Best Cities for 2025
BioAegis Therapeutics7.5.2025 03:48:13 CEST | Press release
BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
Tenaris SA7.5.2025 00:25:22 CEST | Press release
Shareholders approve all resolutions on the agendas of Tenaris’s Annual General Meeting and Extraordinary General Meeting of Shareholders
Calibre Mining Corp.6.5.2025 23:00:26 CEST | Press release
Calibre Receives Court Approval for Arrangement with Equinox Gold
nCino, Inc.6.5.2025 22:35:00 CEST | Press release
nCino to Host 2025 Investor Day
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom